MRD Focus: why measurable residual disease testing is the future
Bruno Paiva et al.
Future of aggressive lymphoma treatment: a shift towards chemo-free regimens
Does TP53-mutated clonal size impact outcomes of CLL patients from the MURANO study?
Improving outcomes for R/R DLBCL with polatuzumab vedotin
Death from infection: reducing the risk in patients with CLL